Actively Recruiting
Clinical Application of CAIX-Targeted PET Imaging in Tumors for Kidney Cancer Diagnosis
Led by Peking University Cancer Hospital & Institute · Updated on 2026-05-15
3
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Renal carcinoma is a common malignant tumor worldwide, with increasing cases and deaths projected by 2025. Early non-invasive diagnosis of clear cell renal cell carcinoma (ccRCC) is important to improve outcomes. This trial investigates the use of CAIX-targeted PET imaging probes, which bind to a protein highly expressed in most ccRCC tumors, to help with early and accurate detection of renal cancer. The study uses a small molecule called RESCA-CAIX-LT that is modified to be stable in the body and labeled with radioactive substances 68Ga or 18F. These probes are administered intravenously at a dose of about 0.05-0.1 mCi/kg. After injection, whole-body dynamic and static PET/CT scans are performed to visualize tumors. The imaging is done using advanced PET/CT equipment and may include delayed scans for unclear lesions. Participants will be patients with renal cancer or suspected cases who are scheduled for biopsy or surgery soon. Researchers will measure the uptake of the imaging probe in tumor lesions to assess diagnostic performance. The trial includes safety monitoring, imaging evaluations, and follow-up to determine how well the probe detects tumors. Participants will be involved in scanning procedures and assessments over the study period.
CONDITIONS
Brief Title
Clinical Application of CAIX-Targeted PET Imaging in Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- Adequate blood counts: WBC 4.0 x10^9/L or neutrophils 1.5 x10^9/L, platelets 100 x10^9/L, hemoglobin 90 g/L
- Coagulation parameters: PT or APTT 1.5 times upper limit of normal
- Liver function: total bilirubin 1.5 times upper limit of normal; ALT/AST 2.5 times upper limit (or 5 times if liver metastases present); ALP 2.5 times upper limit (or 4.5 times if bone or liver metastases present)
- Kidney function: BUN and serum creatinine 1.5 times upper limit of normal
- Normal heart function
- Expected survival of at least 12 weeks
- At least one measurable tumor lesion per RECIST 1.1 criteria
- Women of childbearing age (18-49) must have a negative pregnancy test within 7 days before imaging
- Male and female patients of childbearing potential must agree to use effective contraception during the study and for 3 months after
- Clinician recommends PET/CT for tumor diagnosis or staging
- Ability to understand and consent to the study voluntarily
You will not qualify if you...
- Severe blood, liver, or kidney function abnormalities
- Planning pregnancy
- Pregnant or breastfeeding women
- Unable to lie flat for 30 minutes
- Refusal to participate in the study
- Claustrophobia or psychiatric disorders
- Any condition deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment including blood tests and pregnancy test if applicable
Duration - 1 day
Participants undergo 68Ga/18F-CAIX-LT-BCH PET/CT imaging to diagnose or stage kidney tumors.
1 imaging visit (in-person) including intravenous administration of radioactive tracer and whole-body PET/CT scan
Trial Site Locations
Total: 1 location
1
Peking University Cancer Hospital
Beijing, Haidian, China, 10000
Actively Recruiting
Research Team
L
Lei Xia
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here